Warner Chilcott Meets in Q1 – Zacks Tale of the Tape
Source: http://www.zacks.com/stock/news/20052/Warner+Chilcott+Meets+in+Q1+-+Zacks+Tale+of+the+TapePosted on Monday, May 11th, 2009 | In Market Commentary, Stocks to Watch
Warner Chilcott Ltd.’s (WCRX) announced first-quarter EPS, excluding items, of 39 cents, which matched the consensus.
Revenues expanded 7% to $246 million, primarily due to the growth of Doryx, Loestrin 24 FE and Estrace Cream.
Warner Chillcott indicated that it continues to expect fiscal 2009 revenues to range between $1.015 billion and $1.025 billion.
The developer of woman healthcare products also affirmed full-year earnings guidance of $1.55 to $1.60 per share, excluding items, which is in-line with the $1.59 consensus derived from 12 analysts.
WCRX, Zacks #3 Rank (”Hold”) stock, is about breakeven today with volume of approximately 616,000, which is lower than the average daily volume of about 1.02 million.
“WCRX” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
cent;, Loestrin 24 FE;, Market Commentary, Stocks to Watch, USD, Warner Chilcott Ltd.;, woman healthcare products;, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.